Specialised Therapeutics to distribute European oncology drug
Specialised Therapeutics Australia (STA) has formed an exclusive licence and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the oncology drug APLIDIN (plitidepsin) in Australia and New Zealand.
Obtained from the colonial sea squirt Aplidium albicans, APLIDIN is currently in development for the treatment of multiple myeloma and a type of T cell lymphoma. PharmaMar announced in June that patient recruitment of an international pivotal Phase 3 trial for the drug candidate in refractory/relapsed multiple myeloma had been successfully completed.
Under the terms of the new agreement, PharmaMar will receive an upfront payment, royalties and additional remunerations from STA for regulatory and sales milestones achieved by APLIDIN. PharmaMar will retain production rights and will supply the finished product to STA for exclusive commercial use in Australia and New Zealand.
“This drug is a welcome addition to STA’s expanding oncology portfolio and we look forward to making this treatment option available to patients in Australia and New Zealand, pending the release of pivotal Phase 3 data confirming its efficacy,” said STA CEO Carlo Montagner.
“We applaud PharmaMar’s commitment in developing this important therapy and are delighted to collaborate with a partner of this calibre.”
Oxytocin analogue treats chronic abdominal pain
Researchers have developed a new class of oral painkillers to suppress chronic abdominal pain,...
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
